Article Information
History
- May 12, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Beatriz Carmona-Hidalgo1,
- Isabel González-Mariscal2,
- Adela García-Martín1,
- Francisco Ruiz-Pino3,4,5,
- Giovanni Appendino6,
- Manuel Tena-Sempere3,4,5 and
- Eduardo Muñoz3,4,5,*
- 1Emerald Health Biotechnology, Córdoba, Spain
- 2Instituto de Investigación Biomédica de Málaga-IBIMA, UGC Endocrinología y Nutrición. Hospital Regional Universitario de Málaga, Málaga, Spain
- 3Instituto Maimónides de Investigación Biomédica de Córdoba, Spain
- 4Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Spain
- 5Hospital Universitario Reina Sofía, Córdoba, Spain
- 6Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy
- ↵*Corresponding author: Eduardo Muñoz. Maimónides Biomedical Research Institute of Córdoba, University of Córdoba, Avda Menéndez Pidal s/n. 14004. Córdoba, Spain. Phone: +34 957213766. Email: fi1muble{at}uco.es.
Posted May 12, 2020.
Δ9-Tetrahydrocannabinolic Acid markedly alleviates liver fibrosis and inflammation in murine models of chemically- and obesity-induced liver injury
